New drug combo aims to shrink liver tumors in kidney cancer patients
NCT ID NCT07256223
First seen Dec 04, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This Phase 2 trial is testing whether the combination of envafolimab (an immunotherapy) and lenvatinib (a targeted therapy) can shrink liver tumors in people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 adults who have not received prior treatment for their advanced cancer. Researchers will measure how well the liver tumors respond and how long patients live without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
envafolimab and lenvatinib
What this could lead to
If it works, this combination could offer a new first-line treatment option for people with kidney cancer that has spread to the liver, potentially shrinking liver tumors and extending survival.
What could go wrong
This is a small, early-phase (Phase 2) study with only 30 participants and no comparison group, so results may not apply broadly. The combination may cause side effects and might not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.